Replies to post #2278 on Biotech Values

[mskatiescarletohara]

Recently, OXGN’s CEO and CSO bought $14-15K each of shares on the open market, which I criticized as token, cosmetic purchases

A very feeble attempt to appease shareholder concerns, I think matters are that bad regarding the world leader's VTA...CA4P. There was a reason why BMY pulled out, and the original members of management left when OXGN revealed the Phase I data. Yah, it's the cardiotoxicstuff.

katie....

[DewDiligence]

Where Imasogie bought:

Today’s closing price of 3.84 is very nearly the average price that director Osagie Imasogie paid in his recent $200,000 open-market purchase. FWIW

[DewDiligence]

UPDATED INSIDER SHAREHOLDINGS

[New language has been inserted with respect to Ken Holroyd’s stake, as explained in the previous post.]

Executive officers

ROY LEVITT, CEO
259K shares
1.035M options at exercise prices of $0.40-$11.63

JOHN SKOLAS, CFO
50K shares (joined 10/03)
100K options at $5.19

JOHN ARMSTRONG, EVP (Operations)
50K shares (joined 10/03)
100K options at $4.45

ANGELINE SHASHLO, SVP (Regulatory)
50K shares (joined 6/02)
175K options at $0.40-$2.74

ROGER VOGEL, CMO (acting)
(Dr. Vogel, who joined GENR during 3/04 as the acting Chief medical Officer, is not formally an officer of the company and hence does not file insider trades with the SEC.)

Independent directors

OSAGIE IMASOGIE
51K shares (bought on open market between $3.73-3.96 in 5/04)
20K options at $3.50

FRANK ECOCK
50K shares (bought on open market between $3.53-4.45 in 9/03 and 5/04)
80K options at $0.40-$4.65

ROBERT SHAPIRO
188K shares
100K options at $0.40-$11.63

ZOLA HOROVITZ
29K shares
131K options at $0.40-$10.13

JAMES WYNGAARDEN
5k shares
100K options at $0.40-$10.19

Miscellaneous

Kenneth Holroyd, the former COO, left the company on 3/26/04. On that date, he held 39K shares and 661K options exercisable at $0.40-8.00. It is not known how many shares and options are still held by Dr. Holroyd.